Arcutis (ARQT) CFO tax-related sale of 435 shares after RSU vesting

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. reported that SVP and Chief Financial Officer Latha Vairavan disposed of 435 shares of common stock at $21.05 per share. According to the footnote, the shares were sold to cover tax withholding obligations tied to vesting of Restricted Stock Units. Following this routine tax-related sale, Vairavan directly holds 85,978 common shares.

Insider Trade Summary 10b5-1

Net Seller: 435 shares ($9,157)

Net Sell 1 txn

Insider Vairavan Latha

Role SVP Chief Financial Officer

Sold 435 shs ($9K)

Type	Security	Shares	Price	Value
Sale	Common Stock	435	$21.05	$9K

Holdings After Transaction: Common Stock — 85,978 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 435 shares Sale price: $21.05 per share Shares held after transaction: 85,978 shares +1 more

4 metrics

Shares sold 435 shares Common Stock disposed of on 2026-05-11

Sale price $21.05 per share Open-market sale used to cover tax withholding

Shares held after transaction 85,978 shares Direct common stock holdings after sale

Net shares sold 435 shares transactionSummary netBuySellShares

Key Terms

Restricted Stock Units, tax withholding obligations, open-market sale

3 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vairavan Latha

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		S(1)		435	D	$21.05	85,978	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Remarks:

	/s/ Masaru Matsuda, as Attorney-in-Fact for Latha Vairavan	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Arcutis Biotherapeutics (ARQT) disclose in this Form 4 filing?

Arcutis Biotherapeutics reported that SVP and Chief Financial Officer Latha Vairavan disposed of 435 common shares at $21.05 per share. The filing states this sale was made solely to cover tax withholding obligations from vesting Restricted Stock Units, and she retains 85,978 shares.

How many Arcutis (ARQT) shares did the CFO sell and at what price?

The CFO, Latha Vairavan, sold 435 shares of Arcutis common stock at $21.05 per share. The Form 4 explains that these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units, not as a discretionary market trade.

Why were the Arcutis (ARQT) shares sold by the CFO according to the Form 4?

The Form 4 states the sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units. This means the transaction was a routine tax-management step rather than a discretionary open-market sale reflecting a change in the CFO’s investment stance.

How many Arcutis (ARQT) shares does the CFO hold after this transaction?

After the tax-related sale, SVP and CFO Latha Vairavan directly holds 85,978 shares of Arcutis common stock. This post-transaction balance, disclosed in the Form 4, shows that the 435 shares disposed of represent a small portion of her overall reported holdings.

Does the Arcutis (ARQT) Form 4 indicate any derivative or option exercises?

The Form 4 data show no derivative transactions or option exercises associated with this event. The derivativeSummary is empty, and the footnote clarifies that the reported sale strictly covers tax withholding tied to Restricted Stock Unit vesting, with no separate option exercise disclosed.